ducovest

AGN:NYE-Allergan plc (USD)

EQUITY | Drug Manufacturers—General | New York Stock Exchange

Last Closing

USD 181.08

Change

+2.82 (+1.58)%

Market Cap

USD 70.72B

Volume

3.60M

Analyst Target

USD 197.31
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Allergan PLC is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and distributing generic, brand and biosimilar products.

Company Website : http://www.allergan.com

Currency: AUD

Country : Australia

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-04-08 )

Largest Industry Peers for Drug Manufacturers—General

ETFs Containing AGN

PBI Pitney Bowes Inc 0.00 % 0.79 %

+0.02 (+0.38%)

 USD 0.70B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers—General) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.28% 80% B- 84% B
Dividend Return 0.39% 11% F 20% F
Total Return -4.89% 80% B- 84% B
Trailing 12 Months  
Capital Gain 22.82% 90% A- 95% A
Dividend Return 2.01% 10% F 50% F
Total Return 24.82% 90% A- 95% A
Trailing 5 Years  
Capital Gain -38.04% 10% F 32% F
Dividend Return 3.21% 10% F 12% F
Total Return -34.83% 10% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain -11.87% 9% A- 8% B-
Dividend Return -10.81% 9% A- 7% C-
Total Return 1.06% 9% A- 22% F
Risk Return Profile  
Volatility (Standard Deviation) 18.00% 55% F 53% F
Risk Adjusted Return -60.06% 9% A- 4% F
Market Capitalization 70.72B 10% F 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers—General) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 5.40 60% 28%
Price/Book Ratio 0.97 100% 60%
Price / Cash Flow Ratio 8.10 100% 38%
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity -8.54% 13% 16%
Return on Invested Capital -0.19% 10% 16%
Return on Assets 0.90% 11% 23%
Debt to Equity Ratio 31.14% 90% 76%

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector